Abstract Background: Magnesium sulphate (MgSO 4) has been recommended for fetal
neuroprotection to prevent cerebral palsy, with national societies adopting new guidelines …

Objective To evaluate whether magnesium sulphate (MgSO4) given to women at risk of very‐
preterm birth would be neuroprotective in preterm newborns and would prevent neonatal …

Background Australian and New Zealand clinical practice guidelines, endorsed by the
NHMRC in 2010, recommend administration of antenatal magnesium sulphate to women at …

The aim of our study was to assess the feasibility of implementing a protocol for the use of
magnesium sulfate to prevent cerebral palsy. This retrospective single-center study included …

Background: Cerebral palsy (CP) is a motor and/or cognitive dysfunction affecting the low
birth weight (LBW) infants, and infants delivered preterm before 34 gestational weeks …

Background Magnesium sulphate is currently recommended for neuroprotection of preterm
infants for women at risk of preterm birth at less than 30 weeks' gestation, based on high …

Despite improvements in perinatal care, preterm birth still occurs regularly and the
associated brain injury and adverse neurological outcomes remain a persistent challenge …

Background Survival of preterm infants has improved drastically. In addition to significant
contribution to neonatal mortality, impact of prematurity among survivors may continue …

Background Magnesium sulphate was introduced for fetal neuroprotection in Australia in
2010. The aim of this study was to determine how often antenatal magnesium sulphate is …

[Neuroprotection for preterm infants with antenatal magnesium sulphate]. - Abstract - Europe
PMC Sign in | Create an account https://orcid.org Europe PMC Menu About Tools Developers …